Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer

被引：0

作者：

Motta, R. ^{[1
]}

Cardona, A. ^{[2
]}

Cruz, G. ^{[3
]}

Aliaga, C. ^{[1
]}

Carracedo, C. ^{[1
]}

Raez, L. ^{[4
]}

Arrieta, O. ^{[3
]}

Mezquita, L. ^{[5
]}

Albarran, V. ^{[5
]}

Corrales, L. ^{[6
]}

Bacon, L. ^{[7
]}

Rojas, L.

Zuluaga, J.

Martin, C. ^{[8
]}

Dabalsa, A. ^{[4
]}

Ruiz-Patino, A. ^{[9
]}

Freitas, H. ^{[10
]}

Cordeiro, V. ^{[10
]}

Failoc-Rojas, V. ^{[1
]}

机构：

[1] ALIADA Canc Ctr, Lima, Peru

[2] Luis Carlos Sarmiento Angulo Canc Treatment & Res, Bogota, Colombia

[3] Inst Nacl Cancerol, Mexico City, DF, Mexico

[4] Mem Canc Inst, Hollywood, FL USA

[5] Hosp Clin Barcelona, Barcelona, Spain

[6] CIMCA, San Jose, Costa Rica

[7] Hosp Vivian Pellas, Managua, Nicaragua

[8] Alexander Fleming Inst, Buenos Aires, DF, Argentina

[9] Fdn FICMAC, Bogota, Colombia

[10] AC Camargo Canc Ctr, Sao Paulo, Brazil

来源：

JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期

关键词：

NSCLC; EGFR; Exon20; insertion;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

EP12.01-61

引用

页码：S666 / S666

页数：1

共 50 条

[31] ERBB2 exon 20 insertions are rare in Brazilian non-small cell lung cancer
Cavagna, Rodrigo de Oliveira
Zaniolo, Beatriz Garbe
de Paula, Flavia Escremim
Berardinelli, Gustavo Noriz
Santana, Iara
Albino da Silva, Eduardo Caetano
Dias, Josiane Mourao
Jacinto, Alexandre Arthur
Noleto da Nobrega Oliveira, Rachid Eduardo
de Marchi, Pedro
Leal, Leticia Ferro
Reis, Rui Manuel
THORACIC CANCER, 2022, 13 (23) : 3402 - 3407
[32] AN EVALUATION OF THE ECONOMIC BURDEN AND QUALITY OF LIFE FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH EXON 20 INSERTIONS IN CHINA
Yu, F.
Han, Y.
Zhang, R.
Tou, J.
Ge, Y.
VALUE IN HEALTH, 2022, 25 (01) : S217 - S217
[33] Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'
Inagaki, Yuji
Tamiya, Akihiro
LUNG CANCER, 2020, 148 : 179 - 180
[34] The landscape of EGFR exon 20 insertion mutations in Chinese patients with non-small cell lung cancer.
Xu, Shun
Fu, Zhichao
CANCER RESEARCH, 2022, 82 (12)
[35] New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations
David, Gil-Sierra Manuel
del Pilar, Briceno-Casado Maria
Cristina, Moreno-Ramos
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 934 - 943
[36] Erlotinib Response in a Non-Small Cell Lung Cancer Patient with EGFR Exon 20 Mutation
Korkmaz, Levent
Artac, Mehmet
Karaagac, Mustafa
Er, Zehra
Boruban, Melih C.
Poyraz, Necdet
Kaya, Bugra
Tavli, Lema
Odev, Kemal
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (01): : 64 - 66
[37] Amivantamab for the treatment of EGFR exon 20 insertion mutant non-small cell lung cancer
Vyse, Simon
Huang, Paul H.
EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (01) : 3 - 16
[38] A new era for EGFR exon20 targeting in non-small cell lung cancer
Christopoulos, Petros
CHINESE CLINICAL ONCOLOGY, 2025, 14 (01)
[39] A case of non-small cell lung cancer with EGFR exon 20 insertion treated with osimertinib
Morton-Gittens, Jamie
Pipalia, Nisarg
Liu, Hongxiang
Thippu Jayaprakash, Kamalram
LUNG CANCER, 2021, 156 : S73 - S74
[40] Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Mok, T. S. K.
Liu, G.
Nyaw, S. F.
Curcio, H.
Cortot, A.
Kam, T. Y.
Descourt, R.
Chik, Y. K.
Cheema, P. K.
Gwinnutt, J. M.
Churchill, E. N.
Nyborn, J.
Curran, E.
Yin, Y.
Chong, K.
Tanaka-Chambers, Y.
Kretz, J.
Cadranel, J.
ANNALS OF ONCOLOGY, 2023, 34 : S1698 - S1699

← 1 2 3 4 5 →